Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Timothy P. Sheahan, Amy C. Sims, Rachel L. Graham, Vineet Menachery, Lisa E. Gralinski, James B. Case, Sarah R. Leist, Krzysztof Pyrc, Joy Y. Feng, Iva Trantcheva, Roy Bannister, Yeojin Park, Darius Babusis, Michael O. Clarke, Richard L. MacKman, Jamie E. Spahn, Christopher A. Palmiotti, Dustin Siegel, Adrian S. Ray, Tomas Cihlar & 3 others Robert Jordan, Mark R. Denison, Ralph S. Baric

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Emerging viral infections are difficult to control because heterogeneous members periodically cycle in and out of humans and zoonotic hosts, complicating the development of specific antiviral therapies and vaccines. Coronaviruses (CoVs) have a proclivity to spread rapidly into new host species causing severe disease. Severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) successively emerged, causing severe epidemic respiratory disease in immunologically naïve human populations throughout the globe. Broad-spectrum therapies capable of inhibiting CoV infections would address an immediate unmet medical need and could be invaluable in the treatment of emerging and endemic CoV infections. We show that a nucleotide prodrug, GS-5734, currently in clinical development for treatment of Ebola virus disease, can inhibit SARS-CoV and MERS-CoV replication in multiple in vitro systems, including primary human airway epithelial cell cultures with submicromolar IC50 values. GS-5734 was also effective against bat CoVs, prepandemic bat CoVs, and circulating contemporary human CoV in primary human lung cells, thus demonstrating broad-spectrum anti-CoV activity. In a mouse model of SARS-CoV pathogenesis, prophylactic and early therapeutic administration of GS-5734 significantly reduced lung viral load and improved clinical signs of disease as well as respiratory function. These data provide substantive evidence that GS-5734 may prove effective against endemic MERS-CoV in the Middle East, circulating human CoV, and, possibly most importantly, emerging CoV of the future.

Original languageEnglish (US)
Article numbereaal3653
JournalScience Translational Medicine
Volume9
Issue number396
DOIs
StatePublished - Jun 28 2017
Externally publishedYes

Fingerprint

Coronavirus
Zoonoses
Antiviral Agents
Coronavirus Infections
Severe Acute Respiratory Syndrome
Ebola Hemorrhagic Fever
Active Immunotherapy
Lung
Middle East
Prodrugs
Virus Diseases
Therapeutics
Infection
Viral Load
Inhibitory Concentration 50
GS-5734
Nucleotides
Cell Culture Techniques
Epithelial Cells
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V., Gralinski, L. E., Case, J. B., ... Baric, R. S. (2017). Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science Translational Medicine, 9(396), [eaal3653]. https://doi.org/10.1126/scitranslmed.aal3653

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. / Sheahan, Timothy P.; Sims, Amy C.; Graham, Rachel L.; Menachery, Vineet; Gralinski, Lisa E.; Case, James B.; Leist, Sarah R.; Pyrc, Krzysztof; Feng, Joy Y.; Trantcheva, Iva; Bannister, Roy; Park, Yeojin; Babusis, Darius; Clarke, Michael O.; MacKman, Richard L.; Spahn, Jamie E.; Palmiotti, Christopher A.; Siegel, Dustin; Ray, Adrian S.; Cihlar, Tomas; Jordan, Robert; Denison, Mark R.; Baric, Ralph S.

In: Science Translational Medicine, Vol. 9, No. 396, eaal3653, 28.06.2017.

Research output: Contribution to journalArticle

Sheahan, TP, Sims, AC, Graham, RL, Menachery, V, Gralinski, LE, Case, JB, Leist, SR, Pyrc, K, Feng, JY, Trantcheva, I, Bannister, R, Park, Y, Babusis, D, Clarke, MO, MacKman, RL, Spahn, JE, Palmiotti, CA, Siegel, D, Ray, AS, Cihlar, T, Jordan, R, Denison, MR & Baric, RS 2017, 'Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses', Science Translational Medicine, vol. 9, no. 396, eaal3653. https://doi.org/10.1126/scitranslmed.aal3653
Sheahan, Timothy P. ; Sims, Amy C. ; Graham, Rachel L. ; Menachery, Vineet ; Gralinski, Lisa E. ; Case, James B. ; Leist, Sarah R. ; Pyrc, Krzysztof ; Feng, Joy Y. ; Trantcheva, Iva ; Bannister, Roy ; Park, Yeojin ; Babusis, Darius ; Clarke, Michael O. ; MacKman, Richard L. ; Spahn, Jamie E. ; Palmiotti, Christopher A. ; Siegel, Dustin ; Ray, Adrian S. ; Cihlar, Tomas ; Jordan, Robert ; Denison, Mark R. ; Baric, Ralph S. / Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. In: Science Translational Medicine. 2017 ; Vol. 9, No. 396.
@article{2bfff02d47f24d508713dd4de9905567,
title = "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses",
abstract = "Emerging viral infections are difficult to control because heterogeneous members periodically cycle in and out of humans and zoonotic hosts, complicating the development of specific antiviral therapies and vaccines. Coronaviruses (CoVs) have a proclivity to spread rapidly into new host species causing severe disease. Severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) successively emerged, causing severe epidemic respiratory disease in immunologically na{\"i}ve human populations throughout the globe. Broad-spectrum therapies capable of inhibiting CoV infections would address an immediate unmet medical need and could be invaluable in the treatment of emerging and endemic CoV infections. We show that a nucleotide prodrug, GS-5734, currently in clinical development for treatment of Ebola virus disease, can inhibit SARS-CoV and MERS-CoV replication in multiple in vitro systems, including primary human airway epithelial cell cultures with submicromolar IC50 values. GS-5734 was also effective against bat CoVs, prepandemic bat CoVs, and circulating contemporary human CoV in primary human lung cells, thus demonstrating broad-spectrum anti-CoV activity. In a mouse model of SARS-CoV pathogenesis, prophylactic and early therapeutic administration of GS-5734 significantly reduced lung viral load and improved clinical signs of disease as well as respiratory function. These data provide substantive evidence that GS-5734 may prove effective against endemic MERS-CoV in the Middle East, circulating human CoV, and, possibly most importantly, emerging CoV of the future.",
author = "Sheahan, {Timothy P.} and Sims, {Amy C.} and Graham, {Rachel L.} and Vineet Menachery and Gralinski, {Lisa E.} and Case, {James B.} and Leist, {Sarah R.} and Krzysztof Pyrc and Feng, {Joy Y.} and Iva Trantcheva and Roy Bannister and Yeojin Park and Darius Babusis and Clarke, {Michael O.} and MacKman, {Richard L.} and Spahn, {Jamie E.} and Palmiotti, {Christopher A.} and Dustin Siegel and Ray, {Adrian S.} and Tomas Cihlar and Robert Jordan and Denison, {Mark R.} and Baric, {Ralph S.}",
year = "2017",
month = "6",
day = "28",
doi = "10.1126/scitranslmed.aal3653",
language = "English (US)",
volume = "9",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "396",

}

TY - JOUR

T1 - Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

AU - Sheahan, Timothy P.

AU - Sims, Amy C.

AU - Graham, Rachel L.

AU - Menachery, Vineet

AU - Gralinski, Lisa E.

AU - Case, James B.

AU - Leist, Sarah R.

AU - Pyrc, Krzysztof

AU - Feng, Joy Y.

AU - Trantcheva, Iva

AU - Bannister, Roy

AU - Park, Yeojin

AU - Babusis, Darius

AU - Clarke, Michael O.

AU - MacKman, Richard L.

AU - Spahn, Jamie E.

AU - Palmiotti, Christopher A.

AU - Siegel, Dustin

AU - Ray, Adrian S.

AU - Cihlar, Tomas

AU - Jordan, Robert

AU - Denison, Mark R.

AU - Baric, Ralph S.

PY - 2017/6/28

Y1 - 2017/6/28

N2 - Emerging viral infections are difficult to control because heterogeneous members periodically cycle in and out of humans and zoonotic hosts, complicating the development of specific antiviral therapies and vaccines. Coronaviruses (CoVs) have a proclivity to spread rapidly into new host species causing severe disease. Severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) successively emerged, causing severe epidemic respiratory disease in immunologically naïve human populations throughout the globe. Broad-spectrum therapies capable of inhibiting CoV infections would address an immediate unmet medical need and could be invaluable in the treatment of emerging and endemic CoV infections. We show that a nucleotide prodrug, GS-5734, currently in clinical development for treatment of Ebola virus disease, can inhibit SARS-CoV and MERS-CoV replication in multiple in vitro systems, including primary human airway epithelial cell cultures with submicromolar IC50 values. GS-5734 was also effective against bat CoVs, prepandemic bat CoVs, and circulating contemporary human CoV in primary human lung cells, thus demonstrating broad-spectrum anti-CoV activity. In a mouse model of SARS-CoV pathogenesis, prophylactic and early therapeutic administration of GS-5734 significantly reduced lung viral load and improved clinical signs of disease as well as respiratory function. These data provide substantive evidence that GS-5734 may prove effective against endemic MERS-CoV in the Middle East, circulating human CoV, and, possibly most importantly, emerging CoV of the future.

AB - Emerging viral infections are difficult to control because heterogeneous members periodically cycle in and out of humans and zoonotic hosts, complicating the development of specific antiviral therapies and vaccines. Coronaviruses (CoVs) have a proclivity to spread rapidly into new host species causing severe disease. Severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) successively emerged, causing severe epidemic respiratory disease in immunologically naïve human populations throughout the globe. Broad-spectrum therapies capable of inhibiting CoV infections would address an immediate unmet medical need and could be invaluable in the treatment of emerging and endemic CoV infections. We show that a nucleotide prodrug, GS-5734, currently in clinical development for treatment of Ebola virus disease, can inhibit SARS-CoV and MERS-CoV replication in multiple in vitro systems, including primary human airway epithelial cell cultures with submicromolar IC50 values. GS-5734 was also effective against bat CoVs, prepandemic bat CoVs, and circulating contemporary human CoV in primary human lung cells, thus demonstrating broad-spectrum anti-CoV activity. In a mouse model of SARS-CoV pathogenesis, prophylactic and early therapeutic administration of GS-5734 significantly reduced lung viral load and improved clinical signs of disease as well as respiratory function. These data provide substantive evidence that GS-5734 may prove effective against endemic MERS-CoV in the Middle East, circulating human CoV, and, possibly most importantly, emerging CoV of the future.

UR - http://www.scopus.com/inward/record.url?scp=85021671152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021671152&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aal3653

DO - 10.1126/scitranslmed.aal3653

M3 - Article

VL - 9

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 396

M1 - eaal3653

ER -